Clinical introtumoral chemoimmunotherapy for late stages of lung cancer.

Abstract

e21001 Background: Currently cancer therapy is not satisfied with the effectiveness of available treatment. In addition to surgery, radiotherapy interventional treatment and chemotherapy, engaging the power of immune system of individual patient has been considered as a highly attractive way for cancer treatment. Provenge is an autologous cellular vaccine and represents a significant milestone for cancer immunotherapy. ChemoVac is similarly with Provenge function and plays in kill tumor cells meanwhile induces body own immunological effect against tumors. Methods: Methods: Introtumoral injection of ChemoVac into tumor of NSCLC (39 patients), which is a proprietary therapeutic regimen and composed of three components, i.e. an slow releasing agent, a cytotoxic drug and a hapten. Results: Results: CT guided intratumoral injection into mass of NSCLC, the drug-release controlling agent to effectively coagulate tumor mass for sustained drug release, which improves drug utilization by extending duration of drug in the tumor and reducing dosing frequency. While the injected chemotherapeutic drug kills tumor cells, autologous tumor antigens released from the dead tumor cells by the drug then trigger immune response as a self-vaccination. Meanwhile, a small molecule hapten binds to these antigens and other large carriers to further boost systemic humoral and cellular immunity for suppression and eradication of tumor recurrence and metastasis. Therefore, it resulted in one year survial rate is 36%(treated) compared 14%(control) with P<0.05.in addition to the innovation for sustained drug release, more importantly, ChemoVac provides a new option for cancer treatment by integrating local chemotherapeutic effect with systemic anti-tumor immunity; cell death induced by chemotherapeutic drugs is a priming event and allows the injected tumor act as its own vaccine. Conclusions: Introtumoral injection of ChemoVac is a safe, aggressive (higher drug concentration in the tumor) and cost-effective clinical treatment for solid tumors like NSCLC. ChemoVac displays the following advantages: clinically effective for NSCLC and can repeats introtumoral injections; minimal side effects and better quality of life.